Religare Enterprises Ltd

Religare Enterprises Ltd

Religare Enterprises Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating that Ashish Dhawan has acquired 38,00,000 shares of the company, increasing his holding to 6.35%.

Religare Enterprises Ltd

Religare Enterprises Ltd has informed that its wholly owned subsidiary, Religare Broking Limited, has made an allotment of 421,052,640 equity shares at a premium of INR 13.75 per share, amounting to INR 100,00,00,020, in pursuance of its rights issue.

Religare Enterprises Ltd

Religare Enterprises Limited held its Q1 FY27 earnings conference call on August 13, 2026, discussing its operational and financial performance for the quarter ended June 30, 2026. The company's insurance business, Care, grew at 37% Y-o-Y in GWP terms, making it the second-largest stand-alone health insurer in the country. Religare Finvest is well-capitalized with a net worth of INR915 crores and a healthy cash balance of INR600 crores. The housing finance team is focusing on restoration and rebuilding its franchise.

Religare Enterprises Ltd

Religare Enterprises Ltd has announced a special window for transfer and dematerialisation of physical securities, as per SEBI Circular No. SEBI/ HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026, dated January 30, 2026. The window is open from February 05, 2026 to February 04, 2027, for securities sold/purchased prior to April 01, 2019.

Religare Enterprises Ltd

Religare Enterprises Ltd has made available the audio recording of its earnings call held on August 13, 2026, to discuss its operational and financial performance for the quarter ended June 30, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has published its un-audited standalone and consolidated financial results for the quarter ended June 30, 2026, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Religare Enterprises Ltd

Religare Enterprises Ltd has received a Monitoring Agency Report for the quarter ended June 30, 2026, from CARE Ratings Limited, regarding the utilization of proceeds raised through a Preferential Issue of convertible warrants.

Religare Enterprises Ltd

Religare Enterprises Ltd has announced an investor presentation for an earnings call to be held on August 13, 2026, discussing the company's operational and financial performance for the quarter ended June 30, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has released its un-audited standalone financial statements for the quarter ended June 30, 2026, along with financial results prepared under Regulation 33 of the SEBI Listing Regulations. The company's revenue from operations, interest income, and net profit/loss for the quarter are presented in the attached statement.

Religare Enterprises Ltd

Religare Enterprises Ltd has announced its Q1 FY27 financial results, showing a robust performance. The company's board of directors has approved the unaudited financial results for the quarter ended June 30, 2026, which have been subjected to a limited review by the statutory auditors. The results are in line with the SEBI Listing Regulations. Additionally, the board has re-designated Mr. Arjun Lamba as Managing Director, effective from August 12, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has announced the appointment of Mr Arjun Lamba as Managing Director, effective August 12, 2026. The Board of Directors has also approved the un-audited financial results for the quarter ended June 30, 2026, which have been subjected to a limited review by the statutory auditors.

Religare Enterprises Ltd

Religare Enterprises Ltd's Board of Directors met on August 12, 2026, and considered and approved the Un-Audited Financial Results for the quarter ended June 30, 2026. The Board also approved the re-designation of Mr. Arjun Lamba as Managing Director, effective from August 12, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also re-designated Mr. Arjun Lamba as Managing Director, subject to shareholder approvals. The results and re-designation were approved by the Board at its meeting held on August 12, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has amended its Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information, as per SEBI (PIT) Regulations, 2015.

Religare Enterprises Ltd

Religare Enterprises Ltd has granted 13,195 stock options under the REL ESOP Scheme 2019, with vesting schedule over 5 years and exercise period not later than 8 years.

Religare Enterprises Ltd

Religare Enterprises Ltd has scheduled an earnings call to discuss its operational and financial performance for the quarter ended June 30, 2026.

Religare Enterprises Ltd

Religare Enterprises Ltd has scheduled a board meeting on August 12, 2026, to consider and approve the standalone and consolidated un-audited financial results for the quarter ended June 30, 2026, along with the limited review report of auditors.

Religare Enterprises Ltd

Religare Enterprises Ltd has intimated under Regulation 30 of SEBI LODR Regulations 2015 that the Scheme of Arrangement involving transfer of the Demerged Undertaking to Religare Finvest Limited has not received no-objection / prior approval from the Reserve Bank of India, despite receiving observation letters from National Stock Exchange of India Limited and BSE Limited.

Religare Enterprises Ltd

Religare Enterprises Ltd's material subsidiary, Care Health Insurance Limited, has issued 20,000 unsecured debentures worth Rs. 200 Crore at a 10% coupon rate, listed on the National Stock Exchange of India Limited.

Religare Enterprises Ltd

Religare Enterprises Ltd has allotted 35,00,000 equity shares to Puran Associates Private Limited, a promoter group company, at a premium of Rs. 225 per share, following the conversion of warrants. The allotment has increased the company's issued, subscribed, and paid-up equity share capital from Rs. 3,41,23,37,420 to Rs. 3,44,73,37,420.